The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: Retrospective analysis of 39 patients in Japan

International Journal of Hematology

Volumn 85, Issue 4, 2007, Pages 338-343

  Shimoda, Kazuya ^a,i   Shide, Kotaro ^a,i   Kamezaki, Kenjirou ^a   Okamura, Takashi ^b   Harada, Naoki ^a   Kinukawa, Naoko ^c   Ohyashiki, Kazuma ^d   Niho, Yoshiyuki ^e   Mizoguchi, Hideaki ^f   Omine, Mitsuhiro ^g   Ozawa, Keiya ^h   Harada, Mine ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e CHIHAYA HOSPITAL   (Japan)

^f JAPANESE RED CROSS SOCIETY   (Japan)

^g SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^h JICHI MEDICAL UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Anabolic steroids; Anemia; Myelofibrosis with myeloid metaplasia; Therapy

Indexed keywords

ANABOLIC AGENT; DANAZOL; DOXIFLURIDINE; HEMOGLOBIN; HYDROXYUREA; LIVER ENZYME; MEPITIOSTANE; METENOLONE ACETATE; NANDROLONE DECANOATE; STANOZOLOL;

ACUTE LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE INTOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MYELOFIBROSIS; MYELOID METAPLASIA; SIDE EFFECT; STEROID THERAPY; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANABOLIC AGENTS; ANEMIA; BLOOD TRANSFUSION; CHROMOSOME ABERRATIONS; DANAZOL; ESTROGEN ANTAGONISTS; FEMALE; HEMOGLOBINS; HUMANS; MALE; METHENOLONE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; TIME FACTORS;

EID: 34547543069     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06135     Document Type: Article

References (25)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
2. Ihle JN, Nosaka T, Thierfelder W, Quelle FW, Shimoda K. Jaks and Stats in cytokine signaling. Stem Cells. 1997;15(suppl 1):105-111, discussion 112.
3. Ihle JN. Cytokine receptor signalling. Nature. 1995;377:591-594.
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
8. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling E. Prominent role of TGF-?1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495-3503.
9. Chagraoui H, Tulliez M, Smayra T, et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood. 2003;101:2983-2989.
10. Kakumitsu H, Kamezaki K, Shimoda K, et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res. 2005;29:761-769.
11. Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia: French Society of Bone Marrow Transplantation. Br J Haematol. 1997;98:1004-1009.
12. Guardiola P, Anderson JE, Bandini G, et al, for the International Collaboration for Transplantation in Agnogenic Myeloid Metaplasia. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood. 1999;93: 2831-2838.
13. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102: 3912-3918.
14. Ditschkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant. 2004;34:807-813.
15. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol. 2001;73:194-198.
16. Kennedy BJ. Effect of androgenic hormone in myelofibrosis. JAMA. 1962;182:116-119.
17. Silver RT, Jenkins DE Jr, Engle RL Jr. Use of testosterone and busulfan in the treatment of myelofibrosis with myeloid metaplasia. Blood. 1964;23:341-353.
18. Hast R, Engstedt L, Jameson S, et al. Oxymetholone treatment in myelofibrosis. Blut. 1978;37:19-26.
19. Besa EC, Nowell PC, Geller NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer. 1982;49:308-313.
20. Brubaker LH, Briere J, Laszlo J, et al. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med. 1982;142:1533-1537.
21. Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005;129:771-775.
22. Giovanni B, Michelle E, Letizia C, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma. 2002;43: 2301-2307.
23. Barosi G, Grossi A, Comotti B, Musto P, Gamba B, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114:78-83.
24. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534-2541.
25. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol. 2004;22:424-431.